LTA4H
Basic information
Region (hg38): 12:96000753-96043520
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LTA4H gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 4 | |||||
missense | 20 | 23 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 20 | 4 | 4 |
Variants in LTA4H
This is a list of pathogenic ClinVar variants found in the LTA4H region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-96001014-A-G | not specified | Uncertain significance (Nov 10, 2022) | ||
12-96001015-C-A | not specified | Uncertain significance (Jan 10, 2023) | ||
12-96001062-G-C | not specified | Uncertain significance (Dec 22, 2023) | ||
12-96001065-C-T | not specified | Uncertain significance (Sep 16, 2021) | ||
12-96001105-C-A | not specified | Uncertain significance (Mar 28, 2024) | ||
12-96003014-G-A | not specified | Uncertain significance (Jan 23, 2024) | ||
12-96006381-T-C | not specified | Likely benign (Oct 12, 2021) | ||
12-96006401-T-A | Benign (Jul 31, 2018) | |||
12-96006403-C-T | not specified | Uncertain significance (Mar 28, 2023) | ||
12-96006408-G-A | not specified | Uncertain significance (Aug 16, 2021) | ||
12-96006409-C-T | not specified | Uncertain significance (Jul 12, 2023) | ||
12-96013217-G-A | Benign (Dec 31, 2019) | |||
12-96013781-T-C | not specified | Uncertain significance (Apr 19, 2023) | ||
12-96013817-T-G | not specified | Uncertain significance (Dec 06, 2022) | ||
12-96014866-A-T | not specified | Uncertain significance (Feb 05, 2024) | ||
12-96014959-A-G | not specified | Uncertain significance (Oct 25, 2022) | ||
12-96014963-G-C | not specified | Uncertain significance (Jul 15, 2021) | ||
12-96014985-C-T | Benign/Likely benign (Apr 01, 2022) | |||
12-96015652-G-A | Likely benign (Apr 01, 2022) | |||
12-96018811-A-G | Benign (Jun 18, 2018) | |||
12-96018819-A-C | not specified | Uncertain significance (Dec 15, 2021) | ||
12-96019211-G-C | not specified | Uncertain significance (Dec 28, 2022) | ||
12-96022208-C-T | not specified | Uncertain significance (May 30, 2023) | ||
12-96024492-G-T | not specified | Uncertain significance (Jun 07, 2024) | ||
12-96027509-G-A | not specified | Uncertain significance (Apr 25, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
LTA4H | protein_coding | protein_coding | ENST00000228740 | 19 | 42693 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.96e-8 | 0.999 | 125682 | 0 | 66 | 125748 | 0.000262 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.48 | 242 | 316 | 0.766 | 0.0000151 | 3975 |
Missense in Polyphen | 85 | 108.19 | 0.78565 | 1375 | ||
Synonymous | 1.59 | 92 | 114 | 0.810 | 0.00000568 | 1144 |
Loss of Function | 2.96 | 19 | 39.0 | 0.487 | 0.00000192 | 466 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000517 | 0.000512 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.000324 | 0.000323 |
European (Non-Finnish) | 0.000316 | 0.000308 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.000171 | 0.000163 |
Other | 0.000669 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity. {ECO:0000269|PubMed:11917124, ECO:0000269|PubMed:12207002, ECO:0000269|PubMed:15078870, ECO:0000269|PubMed:18804029, ECO:0000269|PubMed:1897988, ECO:0000269|PubMed:1975494, ECO:0000269|PubMed:2244921}.;
- Pathway
- Arachidonic acid metabolism - Homo sapiens (human);Leukotriene modifiers pathway, Pharmacodynamics;Etodolac Action Pathway;Ketoprofen Action Pathway;Ibuprofen Action Pathway;Rofecoxib Action Pathway;Acetylsalicylic Acid Action Pathway;Diflunisal Action Pathway;Leukotriene C4 Synthesis Deficiency;Acetaminophen Action Pathway;Celecoxib Action Pathway;Sulindac Action Pathway;Diclofenac Action Pathway;Ketorolac Action Pathway;Naproxen Action Pathway;Etoricoxib Action Pathway;Carprofen Action Pathway;Flurbiprofen Action Pathway;Fenoprofen Action Pathway;Antrafenine Action Pathway;Antipyrine Action Pathway;Lumiracoxib Action Pathway;Magnesium salicylate Action Pathway;Trisalicylate-choline Action Pathway;Nepafenac Action Pathway;Phenylbutazone Action Pathway;Lornoxicam Action Pathway;Salsalate Action Pathway;Tenoxicam Action Pathway;Tiaprofenic Acid Action Pathway;Tolmetin Action Pathway;Salicylic Acid Action Pathway;Salicylate-sodium Action Pathway;Oxaprozin Action Pathway;Valdecoxib Action Pathway;Nabumetone Action Pathway;Indomethacin Action Pathway;Meloxicam Action Pathway;Suprofen Action Pathway;Bromfenac Action Pathway;Mefenamic Acid Action Pathway;Arachidonic Acid Metabolism;Piroxicam Action Pathway;Eicosanoid Synthesis;Neutrophil degranulation;Metabolism of lipids;Prostaglandin Leukotriene metabolism;Synthesis of Leukotrienes (LT) and Eoxins (EX);Arachidonic acid metabolism;Innate Immune System;Immune System;Metabolism;Biosynthesis of E-series 18(S)-resolvins;Biosynthesis of E-series 18(R)-resolvins;Biosynthesis of EPA-derived SPMs;Biosynthesis of D-series resolvins;Biosynthesis of aspirin-triggered D-series resolvins;Biosynthesis of protectins;Biosynthesis of DHA-derived SPMs;Biosynthesis of specialized proresolving mediators (SPMs);Fatty acid metabolism;leukotriene biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.208
Intolerance Scores
- loftool
- 0.814
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.45
Haploinsufficiency Scores
- pHI
- 0.120
- hipred
- N
- hipred_score
- 0.492
- ghis
- 0.486
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.999
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Lta4h
- Phenotype
- immune system phenotype;
Zebrafish Information Network
- Gene name
- lta4h
- Affected structure
- epiboly involved in gastrulation with mouth forming second
- Phenotype tag
- abnormal
- Phenotype quality
- delayed
Gene ontology
- Biological process
- proteolysis;leukotriene metabolic process;leukotriene biosynthetic process;long-chain fatty acid biosynthetic process;peptide catabolic process;neutrophil degranulation;cellular lipid metabolic process;cellular protein metabolic process
- Cellular component
- extracellular region;nucleus;nucleoplasm;cytosol;extracellular exosome;tertiary granule lumen;ficolin-1-rich granule lumen
- Molecular function
- RNA binding;aminopeptidase activity;epoxide hydrolase activity;leukotriene-A4 hydrolase activity;protein binding;peptidase activity;zinc ion binding;metalloaminopeptidase activity